Biologics have become the top-selling class of therapeutics that continue to grow as new drugs are approved for an array of disease areas. Ablexis and AlivaMab Biologics have developed a versatile toolbox enabling ‘fit-for-purpose’ antibody discovery and engineering for challenging targets and advanced biologics modalities. Here, we will highlight case studies for the discovery of TCR mimic antibodies, human VHH, and common light chain (CLC) antibodies for engineering into bispecific formats. Our agile antibody discovery and engineering approaches including flexible formats such as VHH and CLC enable rapid discovery of novel antibodies and accelerate efficient reformatting into bispecific and multispecific modalities.